{"transactions":[{"id":1728961,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":107941,"kind":"person","name":"Fontenot Jason D.","position":1,"cik":"0001851761","reported_name":"Fontenot Jason D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-11-28T21:18:40.000Z","date":"2023-11-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1030,"price":0.3821,"value":393.563,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on November 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2023 of $0.3821/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 3,198 shares resulting from the November 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 21,141 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 7,344 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 42,750 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":136270,"source":{"system":"sec-edgar","filing":"0001209191-23-056783","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919123056783/doc4.xml","form_type":"4"}},{"id":1794517,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":107941,"kind":"person","name":"Fontenot Jason D.","position":1,"cik":"0001851761","reported_name":"Fontenot Jason D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-08-29T20:15:43.000Z","date":"2023-08-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1029,"price":0.77,"value":792.33,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on August 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 25, 2023 of $0.77/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 3,199 shares resulting from the August 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 25,369 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 7,344 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 42,750 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":137300,"source":{"system":"sec-edgar","filing":"0001209191-23-047590","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919123047590/doc4.xml","form_type":"4"}},{"id":1875341,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":107941,"kind":"person","name":"Fontenot Jason D.","position":1,"cik":"0001851761","reported_name":"Fontenot Jason D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-05-30T20:42:00.000Z","date":"2023-05-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":1029,"price":1.33,"value":1368.57,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on May 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2023 of $1.33/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 3,199 shares resulting from the May 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 29,597 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 7,344 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 42,750 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":138329,"source":{"system":"sec-edgar","filing":"0001209191-23-032907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919123032907/doc4.xml","form_type":"4"}},{"id":1970046,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":107941,"kind":"person","name":"Fontenot Jason D.","position":1,"cik":"0001851761","reported_name":"Fontenot Jason D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-06T22:07:59.000Z","date":"2023-02-24","kind":"grant","acquired":true,"shares":199500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":199500,"derivative":{"exercise_price":2.66,"expiration_date":"2033-02-23","underlying":"Common Stock","underlying_shares":199500},"source":{"system":"sec-edgar","filing":"0001209191-23-016391","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919123016391/doc4.xml","form_type":"4"}},{"id":1970045,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":107941,"kind":"person","name":"Fontenot Jason D.","position":1,"cik":"0001851761","reported_name":"Fontenot Jason D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-06T22:07:59.000Z","date":"2023-02-25","kind":"tax_withholding","acquired":false,"shares":6559,"price":2.66,"value":17446.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares underlying the portions of RSU grants that vested on February 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2023 of $2.66/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes: (a) 6,306 shares resulting from the February 25, 2023 final vesting installment of the Reporting Person's February 25, 2020 RSU grant, (b) 5,548 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2021 RSU grant and 7,344 shares subject to such RSU grant that will vest in one final installment on February 25, 2024, and (c) 8,530 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 33,825 shares will vest in 8 successive equal quarterly installments thereafter.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":139358,"source":{"system":"sec-edgar","filing":"0001209191-23-016391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919123016391/doc4.xml","form_type":"4"}},{"id":1970044,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":107941,"kind":"person","name":"Fontenot Jason D.","position":1,"cik":"0001851761","reported_name":"Fontenot Jason D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-06T22:07:59.000Z","date":"2023-02-24","kind":"grant","acquired":true,"shares":42750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon settlement of a restricted stock unit (\"RSU\") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":145917,"source":{"system":"sec-edgar","filing":"0001209191-23-016391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919123016391/doc4.xml","form_type":"4"}},{"id":2289894,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":107941,"kind":"person","name":"Fontenot Jason D.","position":1,"cik":"0001851761","reported_name":"Fontenot Jason D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-04-27T21:09:47.000Z","date":"2022-04-25","kind":"tax_withholding","acquired":false,"shares":826,"price":4.83,"value":3989.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of a restricted stock unit (\"RSU\") grant that vested on April 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on April 25, 2022 of $4.83/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 2,508 shares resulting from the April 25, 2022 final annual vesting installment of the Reporting Person's April 25, 2019 RSU grant, (b) 8,335 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in one final annual installment on February 25, 2023, (c) 14,667 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 7,333 shares and 7,334 shares on February 25, 2023 and 2024, respectively, and (continued in footnote 3)"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(d) 45,100 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter.  The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":103167,"source":{"system":"sec-edgar","filing":"0001209191-22-025811","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919122025811/doc4.xml","form_type":"4"}},{"id":2366644,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":107941,"kind":"person","name":"Fontenot Jason D.","position":1,"cik":"0001851761","reported_name":"Fontenot Jason D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-01T22:18:52.000Z","date":"2022-02-25","kind":"grant","acquired":true,"shares":121770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":121770,"derivative":{"exercise_price":5.9,"expiration_date":"2032-02-24","underlying":"Common Stock","underlying_shares":121770},"source":{"system":"sec-edgar","filing":"0001209191-22-014172","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919122014172/doc4.xml","form_type":"4"}},{"id":2366643,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":107941,"kind":"person","name":"Fontenot Jason D.","position":1,"cik":"0001851761","reported_name":"Fontenot Jason D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-01T22:18:52.000Z","date":"2022-02-25","kind":"grant","acquired":true,"shares":45100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."}],"balance_after":103993,"source":{"system":"sec-edgar","filing":"0001209191-22-014172","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919122014172/doc4.xml","form_type":"4"}},{"id":2366642,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":107941,"kind":"person","name":"Fontenot Jason D.","position":1,"cik":"0001851761","reported_name":"Fontenot Jason D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-01T22:18:52.000Z","date":"2022-02-25","kind":"tax_withholding","acquired":false,"shares":6248,"price":5.9,"value":36863.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portions of restricted stock unit (\"RSU\") grants that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 7,565 shares resulting from the February 25, 2022 sole annual vesting installment of the Reporting Person's February 25, 2021 RSU grant, (b) 6,304 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2020 RSU grant and 8,335 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2023, (c) 5,548 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 14,667 shares subject to such RSU grant that will vest in two remaining annual installments of 7,333 shares and 7,334 shares on February 25, 2023 and 2024, respectively, and (see footnote 3)"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(d) 3,334 shares subject to the Reporting Person's April 25, 2019 RSU grant that will vest in one final annual installment on April 25, 2022. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 1,953 shares acquired on April 30, 2021 and 692 shares acquired on October 29, 2021 under the Issuer's 2010 Employee Stock Purchase Plan."}],"balance_after":58893,"source":{"system":"sec-edgar","filing":"0001209191-22-014172","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919122014172/doc4.xml","form_type":"4"}},{"id":2738868,"issuer":{"id":7038,"kind":"organization","name":"SANGAMO THERAPEUTICS, INC"},"owners":[{"id":107941,"kind":"person","name":"Fontenot Jason D.","position":1,"cik":"0001851761","reported_name":"Fontenot Jason D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-04-28T00:49:57.000Z","date":"2021-04-25","kind":"tax_withholding","acquired":false,"shares":811,"price":11.71,"value":9496.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying the portion of restricted stock unit (\"RSU\") grant that vested on April 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on April 23, 2021 of $11.71/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the \"2018 EIP, as amended\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes: (a) 2,522 shares resulting from the April 25, 2021 vesting of the Reporting Person's April 25, 2019 RSU grant and 3,334 shares subject to such RSU grant that will vest on April 25, 2022; (b) 16,667 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in two remaining annual installments of 8,332 shares and 8,335 shares on February 25, 2022 and 2023 respectively; (c) 10,000 shares subject to a grant of RSUs to the Reporting Person on February 25, 2021 which will vest in full on the first anniversary of the grant date; and (continued in footnote 3)"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(d) 22,000 shares subject to a grant of RSUs to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date.  The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended."}],"balance_after":62496,"source":{"system":"sec-edgar","filing":"0001209191-21-028745","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001233/000120919121028745/doc4.xml","form_type":"4"}}]}